惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

U
Unit 42
Vercel News
Vercel News
博客园 - 叶小钗
大猫的无限游戏
大猫的无限游戏
MyScale Blog
MyScale Blog
P
Proofpoint News Feed
量子位
Engineering at Meta
Engineering at Meta
B
Blog RSS Feed
博客园 - 【当耐特】
Recent Announcements
Recent Announcements
Google DeepMind News
Google DeepMind News
D
DataBreaches.Net
Stack Overflow Blog
Stack Overflow Blog
博客园 - 聂微东
小众软件
小众软件
Hugging Face - Blog
Hugging Face - Blog
人人都是产品经理
人人都是产品经理
IT之家
IT之家
T
The Blog of Author Tim Ferriss
Last Week in AI
Last Week in AI
OSCHINA 社区最新新闻
OSCHINA 社区最新新闻
Jina AI
Jina AI
博客园 - 三生石上(FineUI控件)

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Kuros Biosciences AG (CSBTF) Analyst/Investor Day Transcript
SA Transcripts · 2026-06-18 · via All Articles on Seeking Alpha

Kuros Biosciences AG (CSBTF) Analyst/Investor Day June 17, 2026 3:00 AM EDT

Company Participants

Carly Dummer
Christopher Fair - CEO & Director
Joost de Bruijn - President of Innovation and Strategy & Executive Director
G. Ross - Senior Vice President of Marketing & Business Development
Daniel Geiger - Chief Financial Officer
Alexandre Müller

Conference Call Participants

Andy Golberg
Laura Pfeifer-Rossi - Octavian AG, Research Division

Presentation

Carly Dummer

Good morning, everyone. Welcome to Kuros Biosciences Capital Markets Day 2026. It's great to have a full room here in Zurich, and welcome to everybody online as well. I hope you enjoyed the little preview of our new U.S. headquarters in Alpharetta, Georgia. We're very proud to say that, that opened 2 weeks ago for the office staff, and we will be opening for manufacturing in August. It's a 50,000 square foot space. And currently, we occupy 35,000 square foot of that with room for growth. My name is Carly Dummer, Senior Director of Marketing for Kuros. I am very pleased to be here today to introduce you to your hosts and presenters for the morning. I'll share a little bit about the objectives that we have for this session and the agenda before I hand over to Chris.

Okay. So hopefully, you recognize most of these faces. Presenting to you today will be Chris Fair, our CEO; Joost de Bruijn, inventor of MagnetOs and Founder of Kuros. And our President, now our Executive Director and President of Innovation and Strategy; Daniel Geiger, our CFO; Joe Ross, SVP of Marketing. And last but by no means least, we are honored to be joined today by Mr. Andy Golberg. Mr. Golberg is a foot and ankle consultant surgeon practicing in the U.K. He is a leading authority in ankle replacement. And in 2011, he was awarded an OBE by the Queen for his dedication and commitment to medicine. So thank you, Mr. Golberg, for being here today.